Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 845

Sort by

Sort Order Select

Journal Articles

Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma

Blood (2021) 137 (10): 1353–1364.

https://doi.org/10.1182/blood.2020006464

Published: 2021

Includes: Supplemental data

Journal Articles

Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

Blood (2020) 136 (2): 199–209.

https://doi.org/10.1182/blood.2019004537

Published: 2020

Includes: Supplemental data

Journal Articles

Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

Blood (2020) 135 (26): 2375–2387.

https://doi.org/10.1182/blood.2019003382

Published: 2020

Includes: Supplemental data

Journal Articles

The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4–positive T cells that are PD-1–negative

Sanjay S. Patel, Jason L. Weirather, Mikel Lipschitz, Ana Lako, Pei-Hsuan Chen, Gabriel K. Griffin, Philippe Armand, Margaret A. Shipp, Scott J. Rodig

Blood (2019) 134 (23): 2059–2069.

https://doi.org/10.1182/blood.2019002206

Published: 2019

Includes: Supplemental data

Journal Articles

Evaluation of the Functional Landscape of Systemic Immunity in Classical Hodgkin Using a Novel Single Cell Platform (Isolight)

Catherine Diefenbach, MD, Linda Lam, PhD, Bruce G. Raphael, MD, Kenneth B. Hymes, MD, Michael L. Grossbard, MD, Tibor Moskovits, MD, Peter Martin, FRCPC, MD MS, Jia Ruan, MD PhD, John P. Leonard, MD, Pratip Chattopadhyay, PhD

Blood (2019) 134 (Supplement_1): 3980.

https://doi.org/10.1182/blood-2019-128366

Published: 2019

Journal Articles

A Phase II Study of Lenalidomide Plus Rituximab in Patients with Newly Diagnosed Follicular Lymphoma: An Interim Analysis

Zhong Zheng, Li Wang, MD PhD, Shu Cheng, Pengpeng Xu, Weili Zhao, MD PhD

Blood (2019) 134 (Supplement_1): 3984.

https://doi.org/10.1182/blood-2019-126667

Published: 2019

Journal Articles

Myeloid-Derived Suppressor Cells As Potential Contributors to Pregnancy-Associated Lymphoma Progression

Netanel A Horowitz, MD, Noam Bettman, PhD, Ali Abd El Wahed, Tamar Katz, PhD

Blood (2019) 134 (Supplement_1): 3979.

https://doi.org/10.1182/blood-2019-124292

Published: 2019

Journal Articles

Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas

Mahesh Basyal, Weiguo Zhang, MD PhD, Nalini B Patel, Sujan Piya, PhD, Hongying Zhang, MD PhD, William E. Fogler, PhD, William G Rice, PhD, John L. Magnani, PhD, Gautam M. Borthakur, MD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3802.

https://doi.org/10.1182/blood-2019-126030

Published: 2019

Journal Articles

Transcriptome Profiling of Glycosylation Genes Defines Correlation with E-Selectin Ligand Expression and Clinical Outcome in AML

Amanda R. Leonti, MS, Laura Pardo, Todd A. Alonzo, PhD, Robert B. Gerbing, Lisa Eidenschink Brodersen, PhD, Rhonda E. Ries, MA, Jenny L. Smith, MSc, MD, Quy Le, PhD, Richard Aplenc, MD PhD, E. Anders Kolb, MD, John L. Magnani, PhD, William E. Fogler, PhD, Michael R. Loken, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 3772.

https://doi.org/10.1182/blood-2019-124525

Published: 2019

Journal Articles

CCL21 and Dendritic Cell Suppression in Paediatric B Cell Acute Lymphoblastic Leukaemia

Russell D Keenan, MBChB, PhD FRCP, FRCPath, Kate LE Phillips, PhD

Blood (2019) 134 (Supplement_1): 3959.

https://doi.org/10.1182/blood-2019-130093

Published: 2019

Journal Articles

T-Cell Clonal Expansion and Activation Associated with Durable Clinical Response to Dual BTK and CDK4/6 Inhibitor Therapy in Mantle Cell Lymphoma

Christina Y. Lee, MD, Maurizio Di Liberto, PhD, Yang Hu, PhD, Xiangao Huang, PhD, Nancy L Bartlett, MD, Kami J. Maddocks, MD, John P. Leonard, MD, Nils-Petter Rudqvist, PhD, Lorenzo Galluzzi, PhD, Peter Martin, FRCPC, MD MS, Olivier Elemento, PhD, Selina Chen-Kiang, PhD

Blood (2019) 134 (Supplement_1): 3973.

https://doi.org/10.1182/blood-2019-122322

Published: 2019

Journal Articles

ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) + Utomilumab Patients with Refractory Large B Cell Lymphoma

Ran Reshef, MDMSc, David B. Miklos, MD PhD, John M. Timmerman, MD, Caron A. Jacobson, MD MMSc, Nabila N. Bennani, MD, John M. Rossi, MS, Marika Sherman, MS, Lianqing Zheng, PhD, Jennifer Sun, MS, Gabrielle Palluconi, BS, Jenny J. Kim, MD MS, Michael D. Jain, MD PhD

Blood (2019) 134 (Supplement_1): 4084.

https://doi.org/10.1182/blood-2019-123772

Published: 2019

Journal Articles

Phase 1 Results of Anti-PD-Ligand 1 (Durvalumab) & Lenalidomide in Patients with Cutaneous T Cell Lymphoma and Correlation with Programmed Death Ligand 1 Expression and Gene Expression Profile

Christiane Querfeld, MD PhD, Xiwei Wu, PhD, Tracy Stiller, MS, Joycelynne Palmer, PhD, James F Sanchez, PhD, Xochiquetzal Martinez, MD, Steven Rosen, MD, Jasmine Zain, MD

Blood (2019) 134 (Supplement_1): 4024.

https://doi.org/10.1182/blood-2019-126358

Published: 2019

Journal Articles

Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas

Sanjal Desai, MD, Christopher Melani, MD, Kieron Dunleavy, MD, Stefania Pittaluga, MD PhD, Mark A. Ahlman, MD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Mark Roschewski, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 4102.

https://doi.org/10.1182/blood-2019-127481

Published: 2019

Journal Articles

Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase 2 Study

N. Nora Bennani, MD, Grzegorz Nowakowski, MD, Lisa M. Rimsza, MD, Alex A Adjei, MD PhD, Laurence Doyle, Stephen M Ansell, MD PhD

Blood (2019) 134 (Supplement_1): 4090.

https://doi.org/10.1182/blood-2019-129104

Published: 2019

Journal Articles

Duobody-CD3xCD20 Induces Potent Anti-Tumor Activity in Malignant Lymph Node B Cells from Patients with DLBCL, FL and MCL Ex Vivo , Irrespective of Prior Treatment with CD20 Monoclonal Antibodies

Hilma J Van Der Horst, MSc, A. Vera de Jonge, Ida H Hiemstra, PhD, Anne T Gelderloos, MSc, Daniella RAI Berry, Nathalie J Hijmering, Daphne de Jong, Prof Dr, Martine E.D. Chamuleau, Sonja Zweegman, MD PhD, Esther CW Breij, DPhil, Margaretha GM Roemer, PhD, Tuna Mutis

Blood (2019) 134 (Supplement_1): 4066.

https://doi.org/10.1182/blood-2019-125765

Published: 2019

Journal Articles

The Lymphoma Tumor Microenvironment Influences Toxicity after CD19 CAR T Cell Therapy

Michael D. Jain, MD PhD, Rawan Faramand, MD, Verena Staedtke, MD PhD, Renyuan Bai, MBBS, Sae Bom Lee, Hiroshi Kotani, MD PhD, Kayla Reid, Kristen Spitler, Julio Chavez, Bijal Shah, MD, Christina A Bachmeier, PharmD, Marian Dam, ARNP, Brigett Brandjes, PA, Ricardo J Gonzalez, MD, John E Mullinax, MD PhD, Xuefeng Wang, PhD, Mohammad Hussaini, MD, Frederick L. Locke, MD, Marco L. Davila, MD PhD

Blood (2019) 134 (Supplement_1): 4105.

https://doi.org/10.1182/blood-2019-127305

Published: 2019

Journal Articles

A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients with Refractory Large B-Cell Lymphoma (ZUMA-14)

Sattva S Neelapu, MD, Mohamed A Kharfan-Dabaja, MDMBA, Olalekan O. Oluwole, MBBS, MPH, Patel Krish, MD, Ran Reshef, MDMSc, Peter A. Riedell, MD, Parveen Shiraz, MD, Patrick J. Stiff, MD, Jose Villasboas, MD, Lovely Goyal, PhD, Jun Kawashima, Francesca Milletti, PhD, Edward Oliva, Jennifer Sun, MS, Javier Munoz, MD

Blood (2019) 134 (Supplement_1): 4093.

https://doi.org/10.1182/blood-2019-126369

Published: 2019

Journal Articles

Glutamine Depletion By Addicted Myeloma Cells Inhibits Osteoblastic Differentiation of Bone Marrow Mesenchymal Stromal Cells Limiting Asparagine Availability: A Possible New Mechanism for Myeloma Bone Disease

Martina Chiu, PhD, Denise Toscani, PhD, Emanuela Vicario, PhD, Roberta Andreoli, PhD, Giuseppe Taurino, MS, Valentina Marchica, MS, Paola Storti, PhD, Massimiliano Bianchi, PhD, Ovidio Bussolati, MD PhD, Nicola Giuliani

Blood (2019) 134 (Supplement_1): 4339.

https://doi.org/10.1182/blood-2019-128034

Published: 2019

Journal Articles

Higher Intensity of Cell Surface Glucose-Regulated Protein 78 (csGRP78) Expression Is Seen in Patients with Early Progressive Disease/Mortality in a Cohort of Relapsed, Refractory Multiple Myeloma Patients Treated with Carfilzomib, Thalidomide and Dexamethasone

Slavisa Ninkovic, MBBS FRACP FRCPA, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Lenny Straszkowski, BSci Hons, Giulia Quattrocchi, Wee-Joo Chng, MBBS, PhD, Louise E Purton, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD

Blood (2019) 134 (Supplement_1): 4376.

https://doi.org/10.1182/blood-2019-128190

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma

Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4–positive T cells that are PD-1–negative

Evaluation of the Functional Landscape of Systemic Immunity in Classical Hodgkin Using a Novel Single Cell Platform (Isolight)

A Phase II Study of Lenalidomide Plus Rituximab in Patients with Newly Diagnosed Follicular Lymphoma: An Interim Analysis

Myeloid-Derived Suppressor Cells As Potential Contributors to Pregnancy-Associated Lymphoma Progression

Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas

Transcriptome Profiling of Glycosylation Genes Defines Correlation with E-Selectin Ligand Expression and Clinical Outcome in AML

CCL21 and Dendritic Cell Suppression in Paediatric B Cell Acute Lymphoblastic Leukaemia

T-Cell Clonal Expansion and Activation Associated with Durable Clinical Response to Dual BTK and CDK4/6 Inhibitor Therapy in Mantle Cell Lymphoma

ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) + Utomilumab Patients with Refractory Large B Cell Lymphoma

Phase 1 Results of Anti-PD-Ligand 1 (Durvalumab) & Lenalidomide in Patients with Cutaneous T Cell Lymphoma and Correlation with Programmed Death Ligand 1 Expression and Gene Expression Profile

Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas

Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase 2 Study

Duobody-CD3xCD20 Induces Potent Anti-Tumor Activity in Malignant Lymph Node B Cells from Patients with DLBCL, FL and MCL Ex Vivo , Irrespective of Prior Treatment with CD20 Monoclonal Antibodies

The Lymphoma Tumor Microenvironment Influences Toxicity after CD19 CAR T Cell Therapy

A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients with Refractory Large B-Cell Lymphoma (ZUMA-14)

Glutamine Depletion By Addicted Myeloma Cells Inhibits Osteoblastic Differentiation of Bone Marrow Mesenchymal Stromal Cells Limiting Asparagine Availability: A Possible New Mechanism for Myeloma Bone Disease

Higher Intensity of Cell Surface Glucose-Regulated Protein 78 (csGRP78) Expression Is Seen in Patients with Early Progressive Disease/Mortality in a Cohort of Relapsed, Refractory Multiple Myeloma Patients Treated with Carfilzomib, Thalidomide and Dexamethasone

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only